Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.

NCT04572152 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT04572152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.
Lead sponsor
Akeso
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2020
Completion date
August 31, 2023
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors